PARP1 and Ewing sarcoma: Indeed, sensitivity of Ewing sarcoma cell lines to both olaparib and the structurally distinct PARP inhibitor AG-014699 was comparable to that observed in BRCA-deficient cell lines and greater than that observed from other solid bone and soft tissue sarcomas.